Wuxi Bio Acquires Hangzhou CDMO Facility, with Strategic Signal Stronger Than Near-Term Earnings Contribution

Overview

Wuxi Bio announced on August 7, 2026 that it would acquire a CDMO facility in Hangzhou, China from Transcenta for a total consideration of CNY190mn. The facility covers more than 10,000 square meters and can support drug substance production at scales from 20L to 2,000L. Nomura estimates total capacity at around 3,000L. As the added capacity is very small compared with the company's existing scale of over 400,000L, the report believes the transaction will have limited impact on near-term output and revenue, but has strategic implications for expanding the domestic market and integrating idle capacity from biotech companies.

Core views

First, both the financial and capacity scale of the transaction are small: the CNY190mn consideration is not material relative to the company's approximately CNY14.8bn cash and equivalents at FY25-end and its FY26E CNY7.1bn capex plan. Second, the target's utilization rate is low, with only CNY6mn revenue in 2025 and a net loss of CNY58mn, so it may slightly drag on margins during the initial integration period. Third, the acquisition reflects Wuxi Bio's willingness to continue expanding in China's domestic market and also demonstrates its ability to provide CDMO services to biotech companies and integrate existing facilities. Overall, the transaction's strategic signal is stronger than its near-term earnings contribution, and Nomura maintains its Buy rating.

Analysis framework

The report starts with the transaction consideration, payment arrangements, target capacity and operating performance, compares the added capacity of around 3,000L with Wuxi Bio's existing capacity of over 400,000L, and assesses the transaction's importance in light of the company's cash reserves and capex plan; for valuation, it uses a DCF model to determine the 12-month target price.

Methodology notes

• Valuation methodsDiscounted cash flow model

  DCF

  The HKD51.38 target price is based on a DCF model, assuming a WACC of 10.1% and a terminal growth rate of 4.0%.

• Transaction impact analysisComparison of incremental capacity and financial materiality

  Assess the transaction impact by comparing added capacity, transaction consideration and target profit/loss with the acquirer's existing scale.

  The report compares the target's approximately 3,000L capacity with the company's existing capacity of over 400,000L, and incorporates the CNY190mn consideration, approximately CNY14.8bn cash and equivalents, and FY26E CNY7.1bn capex plan to conclude that the near-term earnings impact is limited.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Wuxi Bio（2269.HK）

  Core research subject and acquirer

  Strengths

  Has existing capacity of over 400,000L, approximately CNY14.8bn cash and equivalents, and experience in biologics CDMO services and facility operations.

  Weaknesses

  This acquisition is relatively small in scale and is unlikely to significantly boost near-term revenue; integrating the loss-making facility may slightly drag on short-term margins.

  Comparison

  The target's estimated capacity is around 3,000L, far below Wuxi Bio's existing capacity of over 400,000L.

  Risks

  Intensifying global competition, geopolitical tensions, slower-than-expected improvement in target utilization and higher-than-expected integration costs.

• Transcenta（6628.HK）

  Seller of the CDMO facility, not rated by Nomura

  Strengths

  The facility for sale covers more than 10,000 square meters and can support drug substance production at scales from 20L to 2,000L.

  Weaknesses

  The target's 2025 revenue was only CNY6mn, down 29% year on year, and it recorded a net loss of CNY58mn, indicating significantly low utilization.

  Comparison

  As of June 30, 2026, the target's unaudited book value was around CNY457mn, while the total transaction consideration was CNY190mn.

  Risks

  Continued operating losses at the facility, unsmooth transfer of customers and projects, and uncertainty over transaction closing conditions.

Key data

• Total acquisition considerationCNY190mnPaid in four installments, with proportions of 50%, 15%, 20% and 15%, respectively.
• Target facility areaOver 10,000 square metersThe facility is located in Hangzhou, China.
• Estimated total capacity of the targetAround 3,000LCan support drug substance production at scales from 20L to 2,000L.
• Wuxi Bio's existing capacityOver 400,000LThe new facility accounts for a very low proportion of existing capacity.
• Target's 2025 revenueCNY6mnDown 29% year on year, indicating low facility utilization.
• Target's 2025 net lossCNY58mnFY24 net loss was CNY75mn.
• Unaudited book value of the targetAround CNY457mnAs of June 30, 2026.
• Company cash and equivalentsAround CNY14.8bnAs of FY25-end.
• FY26E capex planCNY7.1bnUsed to assess the materiality of this transaction relative to the company's funding scale.
• FY26F fully diluted EPSCNY1.16The report states that the stock is currently trading at 31.7x FY26F fully diluted EPS.
• Target priceHKD51.38Both rating and target price are maintained unchanged.
• Closing priceHKD41.38As of August 6, 2026.

Impact & implications

The direct incremental contribution of this transaction to Wuxi Bio's overall manufacturing capability and near-term revenue is limited, because the target's approximately 3,000L capacity is very small relative to the company's existing capacity of over 400,000L. Since the target has low revenue and remains loss-making, facility ramp-up, customer onboarding and cost integration may slightly drag on margins in the short term. However, the low transaction consideration and the company's ample cash reserves limit financial pressure; over the medium to long term, the transaction will help the company strengthen its domestic footprint and may create an integration path for acquiring idle capacity from biotech companies, introducing customer projects and improving utilization.

Risks

• Intensifying competition in the global CDMO industry may affect orders, pricing and profitability.
• Geopolitical tensions may affect cross-border customer demand and the company's business expansion.
• The acquired facility has significantly low utilization; if customer onboarding and capacity ramp-up are slower than expected, losses may continue.
• Higher-than-expected integration and operating costs may put greater pressure on short-term margins.
• If the company's earnings fall below valuation assumptions, the HKD51.38 target price may not be achieved.

What to watch

• Transaction closing progress and payment status of the four installments.
• Customer project onboarding, order conversion and pace of capacity utilization improvement at the Hangzhou facility.
• Changes in facility revenue, losses and margins after the acquisition.
• The company's plans for further acquisitions or capacity expansion in China's domestic market.
• Execution of the FY26E CNY7.1bn capex plan and cash consumption.
• Impact of global competition and the geopolitical environment on overseas customer orders.